Denali Therap
DNLI23.0205.46% ( -1.330 )
Denali Therap (DNLI)
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The compan...
- Open
- 24.340
- High
- 24.350
- Low
- 22.990
- Prev. Close
- 24.350
- Volume
- 1.23M
- Turnover
- 28.69M
- Avg Price
- 23.284
- Bid/Ask Ratio
- --
- Amplitude
- 5.59%
- 52wk High
- 27.300
- Volume Ratio
- 0.95
- Turnover Ratio
- 0.85%
Denali Therap Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$34.3149.06%
Forecast & RatingStrong buy
20analysts
- Strong buy85.00%
- Buy10.00%
- Hold5.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 11 hours ago
Groupama Asset Managment Grows Stock Position in Denali Therapeutics Inc. $DNLI
- PUBT · Jul 28 at 05:04 AM
Denali Therapeutics sells priority review voucher for $195 million gross proceeds
- PUBT · Jul 27 at 03:01 PM
Denali Therapeutics schedules quarterly results release and conference call
- Tip Ranks · Jul 21 at 05:40 PM
Goldman Sachs Remains a Buy on Denali Therapeutics (DNLI)
- Simplywall · Jul 19 at 04:15 PM
Denali Therapeutics (DNLI) Heads To Alzheimer’s Conference As Valuation Questions Return
- Tip Ranks · Jul 13 at 10:15 AM
Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI)
